Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BRONKAID MIST vs AEROLATE SR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Epinephrine, the active ingredient, is a direct-acting sympathomimetic amine that stimulates alpha- and beta-adrenergic receptors. Beta-2 receptor activation in bronchial smooth muscle causes bronchodilation. Alpha receptor activation causes vasoconstriction, reducing mucosal edema.
AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.
Temporary relief of bronchial asthma,Relief of mild symptoms of intermittent asthma,Relief of wheezing and shortness of breath in asthma
Treatment of symptoms and reversible airway obstruction associated with chronic asthma,Chronic obstructive pulmonary disease (COPD),Apnea of prematurity (off-label)
2 inhalations (200 mcg per inhalation) every 4 hours as needed for bronchospasm. Maximum 12 inhalations in 24 hours.
400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.
Terminal elimination half-life: 3-6 hours; clinical context: shorter half-life in children, prolonged in hepatic impairment; requires frequent dosing
Terminal elimination half-life 12 hours (range 10–15 h) in adults; prolonged in hepatic impairment (up to 24 h) and elderly.
Metabolized primarily by monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT) in the liver and other tissues.
Primarily hepatic via cytochrome P450 enzymes (CYP1A2, CYP2E1, and CYP3A4). Theophylline is metabolized to 1,3-dimethyluric acid, 1-methyluric acid, and 3-methylxanthine.
Renal: 40-70% unchanged; fecal: minor (biliary) <5%
Renal: 60% as unchanged drug; biliary/fecal: 30% as metabolites; 10% as unchanged in feces.
55% bound primarily to albumin
55–65% bound to plasma proteins, primarily albumin.
Vd: 1-2 L/kg; reflects extensive distribution into tissues, particularly lungs
0.4–0.6 L/kg, indicating distribution into total body water.
Inhalation: 10-20% (systemic); oral: 40-60% (variable due to first-pass metabolism)
Oral: 90–100% for sustained-release formulation; food decreases rate but not extent (AUC unchanged).
No dose adjustment required for renal impairment. Drug is primarily hepatically metabolized.
No dose adjustment required for renal impairment.
No specific dose adjustment guidelines available. Use with caution in severe hepatic impairment (Child-Pugh class C) due to potential for increased systemic exposure.
Use with caution in severe hepatic impairment (Child-Pugh class C); consider dose reduction by 50%.
Not recommended for children under 12 years of age. For children 12 years and older, same as adult dosing: 2 inhalations every 4 hours as needed, max 12 inhalations per day.
Children 6-12 years: 200-400 mcg inhaled twice daily. Children over 12 years: same as adult dose.
No specific dose adjustment required. Use with caution due to increased risk of tachycardia, hypertension, and CNS stimulation. Consider starting at lower doses if tolerated.
Start at lower end of dosing range (400 mcg twice daily) and titrate to response; monitor for systemic effects.
None
No FDA black box warning exists for this drug.
Do not use if solution is brown or cloudy,Do not use if more than the number of inhalations prescribed per 24 hours are needed,May cause increased blood pressure, tachycardia, and other cardiovascular effects,May cause nervousness, tremor, or insomnia,Do not exceed recommended dosage
Theophylline has a narrow therapeutic index; serum levels must be monitored to avoid toxicity. Toxicity can include seizures, cardiac arrhythmias, and death. Caution in patients with heart failure, hepatic impairment, or those over 55 years. Risk of toxicity increased by concurrent medications such as cimetidine, fluoroquinolones, and macrolides.
Hypersensitivity to epinephrine or any component,Cardiac arrhythmias associated with tachycardia or myocardial insufficiency,Concurrent use with monoamine oxidase inhibitors (MAOIs) or within 2 weeks of discontinuing MAOIs,Narrow-angle glaucoma,Labor and delivery (may delay second stage),Hypertension, hyperthyroidism, or diabetes (relative contraindications)
Hypersensitivity to theophylline or any component of the formulation; active seizure disorder; untreated cardiac arrhythmias; severe hypertension; hyperthyroidism; peptic ulcer disease; caution with concurrent use of ephedrine or other sympathomimetics.
Avoid caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they may increase the risk of cardiovascular side effects such as palpitations and tachycardia. No other significant food interactions are known.
High-fat meals may delay absorption. Avoid charcoal-grilled foods and large amounts of caffeine. Grapefruit juice may increase theophylline levels; limit intake.
FDA Pregnancy Category C. First trimester: Inadequate human data; animal studies show no teratogenicity at clinically relevant doses but fetal toxicity at high doses. Second/third trimesters: Risk of fetal tachycardia, hypoglycemia, and transient neonatal hyperexcitability due to beta-agonist effects. Avoid use near term due to potential for uterine relaxation and delayed labor.
Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypoglycemia, and reduced uterine contractility; avoid use near term due to potential for neonatal bradycardia and hypoglycemia.
Epinephrine (active ingredient) is excreted in breast milk in minimal amounts. M/P ratio not established. Short-acting beta-agonist use is considered compatible with breastfeeding; however, monitor infant for irritability and tachycardia.
Salbutamol is excreted into breast milk in minimal amounts; estimated infant dose <2% of maternal weight-adjusted dose. No known adverse effects in nursing infants. M/P ratio not established. Use with caution.
No specific dose adjustments recommended; however, use lowest effective dose due to increased clearance and larger volume of distribution. Closely monitor for maternal and fetal effects; consider alternative agents if frequent dosing required.
No dose adjustment required for inhaled salbutamol. Increased clearance in late pregnancy may necessitate higher doses for systemic effects; monitor clinical response and adjust accordingly.
BRONKAID MIST contains epinephrine, a non-selective adrenergic agonist. Inhaled epinephrine is rapidly absorbed and can cause tachycardia, hypertension, and cardiac arrhythmias. It is contraindicated in patients with coronary artery disease, hypertension, or hyperthyroidism. Use with caution in patients with diabetes, as it may increase blood glucose. Note that BRONKAID MIST delivers a fixed dose; repeated use more than every 3-4 hours or exceeding 12 inhalations in 24 hours may indicate inadequate control and need for medical evaluation.
AEROLATE SR contains theophylline; narrow therapeutic index (10-20 mcg/m L). Monitor serum levels, especially with CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine) or inducers (e.g., carbamazepine, phenytoin). SR formulation avoids peak-trough fluctuations; do not crush or chew. Caution in heart failure, hepatic impairment, and elderly.
Do not use if you have heart disease, high blood pressure, diabetes, or thyroid disease without consulting a doctor.,Seek emergency medical help if symptoms worsen or do not improve after 20 minutes.,Do not exceed 12 inhalations in 24 hours or use more often than every 4 hours.,If you miss a dose, take it as soon as you remember, but do not double up.,Keep away from children; accidental ingestion can be fatal.,Store at room temperature away from heat and open flame (pressurized container).,Do not puncture or incinerate the canister, even when empty.
Take exactly as prescribed; do not crush or chew the sustained-release tablet.,Do not stop suddenly; sudden withdrawal may worsen breathing.,Avoid excessive caffeine (coffee, tea, chocolate) as it may increase side effects.,Report nausea, vomiting, insomnia, palpitations, or seizures immediately.,Keep regular appointments for blood level monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BRONKAID MIST vs AEROLATE SR, answered by our medical review team.
BRONKAID MIST is a Bronchodilator that works by Epinephrine, the active ingredient, is a direct-acting sympathomimetic amine that stimulates alpha- and beta-adrenergic receptors. Beta-2 receptor activation in bronchial smooth muscle causes bronchodilation. Alpha receptor activation causes vasoconstriction, reducing mucosal edema.. AEROLATE SR is a Bronchodilator that works by AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BRONKAID MIST and AEROLATE SR depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BRONKAID MIST is: 2 inhalations (200 mcg per inhalation) every 4 hours as needed for bronchospasm. Maximum 12 inhalations in 24 hours.. The standard adult dose of AEROLATE SR is: 400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BRONKAID MIST and AEROLATE SR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BRONKAID MIST is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; animal studies show no teratogenicity at clinically relevant doses but fetal toxicity at high doses. Second/third . AEROLATE SR is classified as Category C. Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.